Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE N/A. (2001–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $15M | $5M | $12M | $16M | $60M | $145M | $153M | $109M | $74M | $74M | $47M |
| Enterprise Value | $16M | $5M | $13M | $16M | $63M | $132M | $123M | $111M | $73M | $72M | $47M |
| P/E Ratio → | -1.26 | — | 1.04 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 7.52 | 4.32 | — | 14.74 | 12.65 | 4.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 200.0% | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | 6284.4% | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | 6353.3% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -297.4% | -89.2% | -273.7% | — | -256.0% | -62.8% | -41.5% |
| ROA | -809.3% | -809.3% | 384.9% | -271.6% | -128.7% | -60.7% | -110.1% | -261.8% | -123.2% | -44.6% | -35.8% |
| ROIC | — | — | — | — | -634.2% | -353.4% | — | — | -282.4% | -58.8% | -33.1% |
| ROCE | — | — | — | — | -219.6% | -77.9% | -219.2% | — | -258.1% | -63.4% | -42.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.26 | 0.20 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -0.71 | -0.86 | — | -0.19 | -0.42 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -149.95 | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Quick Ratio | 0.03 | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 0.17 | 0.34 | 3.50 | 3.73 | 0.03 | 1.14 | 1.40 | 11.56 |
| Asset Turnover | — | — | — | — | — | — | — | -0.06 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 96.5% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $9M | $5M | $4M | $2M | $2M | $2M | $2M | $1M | $1M | $1M |
Imminent Insolvency and Dilution
As reported in recent financial filings, BCLI's current ratio has plummeted to 0.02, reflecting a near-total depletion of liquid assets that leaves the company with only $29,000 in cash, a figure that appears insufficient to support even basic operational continuity without immediate, highly dilutive external financing.
The current ratio of 0.02 indicates that the company lacks the necessary working capital to meet its short-term obligations, suggesting an extreme risk of insolvency. Investors should monitor the company's ability to secure emergency funding, as the current liquidity position is effectively non-existent compared to historical norms.
Based on reported figures, the company's days payable outstanding has surged to 17,494 days in 2026Q1, which suggests that BCLI is likely deferring payments to vendors as a desperate measure to preserve its negligible cash reserves rather than maintaining standard operational efficiency or supplier relationships.
This extreme DPO level indicates that the company is likely facing significant pressure from creditors and may be unable to settle its liabilities in the normal course of business. Such metrics suggest that the company's operational efficiency is severely compromised by its ongoing liquidity crisis.
According to comparative financial data, BCLI's negative return on assets of -3.3% in 2026Q1 highlights a structural disadvantage when measured against peers like Fate Therapeutics, as the company lacks the capital base to sustain the R&D intensity required to compete in the neurodegenerative cell therapy space.
The gap between BCLI and its peers appears to be widening as the company's inability to generate revenue forces it to prioritize survival over platform development. This suggests that the company is falling behind in the competitive landscape, making it increasingly difficult to achieve the scale necessary for commercial viability.
As noted in market analysis, the P/E ratio is frequently misapplied to BCLI, as the company's negative earnings and lack of revenue render traditional valuation multiples entirely meaningless for assessing the intrinsic value of its proprietary MSC-NTF platform or its potential for future regulatory success.
Investors should instead focus on the cash burn rate and the probability-weighted value of the regulatory pipeline, as traditional valuation metrics obscure the reality of the company's pre-revenue status. Relying on P/E or EV/EBITDA in this context may lead to a fundamental misunderstanding of the company's financial risk profile.
Includes 30+ ratios · 24 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCLI stock.
Brainstorm Cell Therapeutics Inc.'s current P/E ratio is -1.3x. The historical average is 1.0x.
Based on historical data, Brainstorm Cell Therapeutics Inc. is trading at a P/E of -1.3x. Compare with industry peers and growth rates for a complete picture.